Metabolic and renal benefits of using sodium-glucose cotransporter type 2 inhibitors in patients with type 1 diabetes mellitus and continuous subcutaneous insulin infusion | Synapse
May 6, 2024
Metabolic and renal benefits of using sodium-glucose cotransporter type 2 inhibitors in patients with type 1 diabetes mellitus and continuous subcutaneous insulin infusion
Key Points
Key points are not available for this paper at this time.
Abstract
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)